CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (36,594)	$ (35,368)
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:
Depreciation and amortization	3,589	3,007
Amortization of debt issuance costs and debt discount	6,003	3,124
Write-off of assets from clinical trials segment	2,398	0
Share-based compensation	2,210	7,474
Change in fair value of liability classified warrants	96	(552)
Change in fair value of liability classified conversion option derivatives	7,296	(2,568)
Unrealized loss (gain) on investments	0	(121)
Accretion of discount on investment securities	0	(451)
Deferred taxes	(32)	0
Loss on disposal of property and equipment	0	50
Changes in operating assets and liabilities:
Accounts receivable	(8,969)	(11,657)
Other receivables	(228)	201
Inventories	(5,747)	2,356
Prepaid expenses and other current assets	1,250	(108)
Other assets	3	(21)
Accounts payable	11,490	898
Change in operating leases	(120)	384
Accrued expenses and other current liabilities	2,262	1,976
Other non-current liabilities	(97)	(167)
Net cash and cash equivalents used in operating activities	(15,190)	(31,543)
Cash flows from investing activities:
Purchases of property and equipment	(1,536)	(2,436)
Proceeds from asset disposition	126	0
Sales of marketable securities/investments	0	40,000
Net cash and cash equivalents (used in) provided by investing activities	(1,410)	37,564
Cash flows from financing activities:
Proceeds from private placement, net of offering costs	15,359	0
Payments made for financing of insurance payments	(456)	(1,002)
Payment of deferred consideration liability for acquisition	0	(2,140)
Principal payments on long-term debt	(20,000)	0
Principal payments on financing leases	(20)	(18)
Common stock issued for options exercised	2,340	75
Net cash and cash equivalents used in financing activities	(2,777)	(3,085)
Net (decrease) increase in cash and cash equivalents	(19,377)	2,936
Cash and cash equivalents at beginning of period	49,669	33,488
Cash and cash equivalents at end of period	30,292	36,424
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets in connection with operating lease modifications	1,253	783
Principal exchange of convertible note for preferred stock	4,111	0
Purchases of property and equipment included in accounts payable	528	423
Financed insurance premiums	540	0
Cash paid for:
Interest	$ 2,158	$ 2,224